ARTICLE | Discovery & Translation
BioCentury’s roundup of translational innovations
By Danielle Golovin, Biopharma Analyst
August 19, 2023 12:52 AM UTC
A team including Nathanael Gray from Stanford University, Taebo Sim from Korea University and Ha-Soon Choi from Magicbullettherapeutics Inc. reported in Cell Chemical Biology a bivalent proteolysis targeting chimera (PROTAC), KYH1872, that can induce proximity between ubiquitin E3 ligase KLHDC2 and target kinases to induce degradation of them.
Most degraders utilize E3 ligases CRBN or VHL, but there are 600 E3 ligases in the human genome and adding others to the degrader toolbox could enable degradation of a wider range of targets…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Automotive / EVs, Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- ChartPrime. Elevate your Trading Game with ChartPrime. Access Here.
- BlockOffsets. Modernizing Environmental Offset Ownership. Access Here.
- Source: https://www.biocentury.com/article/648990/protac-using-an-alt-e3-ligase-plus-lung-targeted-mrna-covid-vaccine-and-more
